New Discoveries Make It Harder for HIV to Hide from Drugs

July 2011
International Journal of Virology;2011, Vol. 7 Issue 2, p72
Academic Journal
No abstract available.


Related Articles

  • Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Mesplède, Thibault; Quashie, Peter K.; Osman, Nathan; Han, Yingshan; Singhroy, Diane N.; Lie, Yolanda; Petropoulos, Christos J.; Huang, Wei; Wainberg, Mark A. // Retrovirology;2013, Vol. 10 Issue 1, p1 

    Background: Clinical studies have shown that integrase strand transfer inhibitors can be used to treat HIV-1 infection. Although the first-generation integrase inhibitors are susceptible to the emergence of resistance mutations that impair their efficacy in therapy, such resistance has not been...

  • HIV Genetic Diversity and Drug Resistance. Santos, André F.; Soares, Marcelo A. // Viruses (1999-4915);Feb2010, Vol. 2 Issue 2, p503 

    Most of the current knowledge on antiretroviral (ARV) drug development and resistance is based on the study of subtype B of HIV-1, which only accounts for 10% of the worldwide HIV infections. Cumulative evidence has emerged that different HIV types, groups and subtypes harbor distinct biological...

  • Blocking premature reverse transcription fails to rescue the HIV-1 nucleocapsid-mutant replication defect. Thomas, James A.; Shatzer, Teresa L.; Gorelick, Robert J. // Retrovirology;2011, Vol. 8 Issue 1, p46 

    Background: The nucleocapsid (NC) protein of HIV-1 is critical for viral replication. Mutational analyses have demonstrated its involvement in viral assembly, genome packaging, budding, maturation, reverse transcription, and integration. We previously reported that two conservative NC mutations,...

  • Persistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks. Sáez-Cirión, Asier; Versmisse, Pierre; Truong, Lien X.; Chakrabarti, Lisa A.; Carpentier, Wassila; Barré-Sinoussi, Françoise; Scott-Algara, Daniel; Pancino, Gianfranco // Retrovirology;2006, Vol. 3, p81 

    Background: We have previously reported that CD4 T cells from some exposed uninfected (EU) Vietnamese intravenous drug users are relatively resistant to HIV infection in vitro. Here, we further characterized the restriction of viral replication in CD4 T cells from five EUs and assessed its...

  • Selection dramatically reduces effective population size in HIV-1 infection. Yi Liu; Mittler, John E. // BMC Evolutionary Biology;2008, Vol. 8, Special section p1 

    Background: In HIV-1 evolution, a 100-100,000 fold discrepancy between census size and effective population size (Ne) has been noted. Although it is well known that selection can reduce Ne, high in vivo mutation and recombination rates complicate attempts to quantify the effects of selection on...

  • Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. Mesplède, Thibault; Osman, Nathan; Wares, Melissa; Quashie, Peter K.; Hassounah, Said; Anstett, Kaitlin; Han, Yingshan; Singhroy, Diane N.; Wainberg, Mark A. // Journal of Antimicrobial Chemotherapy (JAC);Oct2014, Vol. 69 Issue 10, p2733 

    Background The results of several clinical trials suggest that the integrase inhibitor dolutegravir may be less prone than other drugs to the emergence of HIV drug resistance mutations in treatment-naive patients. We have shown that the R263K mutation commonly emerged during tissue culture...

  • Control of M184V HIV-1 mutants by CD8 T-cell responses. Vollbrecht, Thomas; Eberle, Josef; Roider, Julia; Bühler, Silja; Stirner, Renate; Henrich, Nadja; Seybold, Ulrich; Bogner, Johannes; Draenert, Rika // Medical Microbiology & Immunology;May2012, Vol. 201 Issue 2, p201 

    Antiretroviral treatment directed against HIV is highly effective, yet limited by drug resistance mutations. We hypothesized that CD8 T cells targeting drug-resistant HIV mutants are able to inhibit viral replication in the setting of a failing therapeutic regimen. We evaluated CD8 T-cell...

  • Preventing and Managing Antiretroviral Drug Resistance. Kuritzkes, Daniel R. // AIDS Patient Care & STDs;May2004, Vol. 18 Issue 5, p259 

    Development of resistance to antiretroviral drugs (ARVs) is a major impediment to optimum treatment of HIV-1 infection. Although resistance testing can help to select subsequent regimens when virologic failure occurs, cross-resistance, which affects all classes of ARVs, may make it more...

  • HIV Drug Resistance Mutations (DRMs) Detected by Deep Sequencing in Virologic Failure Subjects on Therapy from Hunan Province, China. Chen, Xi; Zou, Xiaobai; He, Jianmei; Zheng, Jun; Chiarella, Jennifer; Kozal, Michael J. // PLoS ONE;2/19/2016, Vol. 11 Issue 2, p1 

    Objective: Determine HIV drug resistance mutations (DRMs) prevalence at low and high levels in ART-experienced patients experiencing virologic failure (VF). Methods: 29 subjects from 18 counties in Hunan Province that experienced VF were evaluated for the prevalence of DRMs (Stanford DRMs with...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics